Publications

Sort By:
Filters:
Filters
Filters

 

Molecule
Show (4)
Cancel
Filters
Filters

 

Journal/Publisher
Show (4)
Cancel

PUBLISH DATE

TITLE

MOLECULE

JOURNAL PUBLISHER

09/04/2021

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

Saroglitazar

Journal of Hepatology

06/23/2021

Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator- Activated Receptor Story Goes On!

Saroglitazar

Hepatology (AASLD)

04/02/2021

Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial

Saroglitazar

Hepatology (AASLD)

06/19/2020

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

Saroglitazar

Cardiovascular Diabetology